NICM
IMNM icon

Neo Ivy Capital Management’s Immunome IMNM Stock Holding History

Neo Ivy Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,635
Closed -$4.14M – 416
2025
Q4 		$4.14M Buy
+192,635
New +$3.38M 0.65% 49

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Neo Ivy Capital Management's IMNM Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Immunome (IMNM) in Q1 2026, closing a stake of 192,635 shares — an estimated $4.14M sold.

Neo Ivy Capital Management first reported a position in IMNM in Q4 2025 and held it in 1 quarter. The position peaked at $4.14M in Q4 2025. 201 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Neo Ivy Capital Management reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 192,635 Immunome shares in Q1 2026, an estimated $4.14M.
  • Neo Ivy Capital Management first reported a position in Immunome in Q4 2025 and held it in 1 quarter.
  • Neo Ivy Capital Management's Immunome position peaked at $4.14M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.